Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain

Published:2024-07-11 Issue: Volume: Page:1-9
ISSN:1362-5187
Container-title:The European Journal of Contraception & Reproductive Health Care
language:en
Short-container-title:The European Journal of Contraception & Reproductive Health Care

Author:

Conde José C. Quílez¹,Parra Ribes Inmaculada²,Perelló-Capo Josep³⁴,Lobo Abascal Paloma⁵⁶,García Ignacio Cristóbal⁷,Andeyro García Mercedes⁸⁹,Gutiérrez Alés José¹⁰,Herrero Conde Mercedes¹¹,Rius Tarruella Joan¹²^ORCID,Espinós Lafuente Belén¹³

Affiliation:

1. President of the Spanish Society of Contraception (SEC), 2022 – 2024. Servicio Ginecología y Obstetricia, Hospital Universitario de Basurto, Bilbao, Spain

2. Unidad de Salud Sexual y Reproductiva de Sueca, Hospital Universitario de "La Ribera". Consejería Valenciana de Sanidad, Valencia, Spain

3. Servicio de Ginecología y Obstetricia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

4. Universitat Autònoma de Barcelona, Barcelona, Spain

5. Servicio de Ginecología y Obstetricia, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain

6. Universidad Europea, Madrid, Spain

7. Servicio de Ginecología y Obstetricia, Hospital Clínico San Carlos, Universidad Francisco de Vitoria, Madrid, Spain

8. Head of Servicio de Ginecología y Obstetricia, Hospital Universitario General de Villalba, Madrid, Spain

9. Universidad Alfonso X El Sabio, Madrid, Spain

10. President of the Spanish Contraception Foundation (FEC), Madrid, Spain

11. Servicio de Ginecología y Obstetricia, Hospital HM, Madrid, Spain

12. Departamento Médico, Bayer Hispania S.L, Sant Joan Despí, Barcelona, Spain

13. Departamento de Market Access, Bayer Hispania S.L, Sant Joan Despí, Barcelona, Spain

Funder

Bayer Hispania S.L

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13625187.2024.2369843

Reference36 articles.

1. Direct costs of unintended pregnancy in Spain

2. SEC (Sociedad Española de Contracepción). Encuesta SEC de Anticoncepción en España 2022 [Internet]; SEC Sociedad española de contracepcion. 2022. p. 9–11. https://sec.es/encuesta-sec-de-anticoncepcion-en-espana-2022-y-12/

3. Economic Burden of Contraception Management in Spain

4. Contraceptive failure in the United States

5. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review